556 related articles for article (PubMed ID: 12879812)
1. [Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Tapia C; González P; Pereira A; Pérez J; Noriega LM; Palavecino E
Rev Med Chil; 2003 May; 131(5):515-9. PubMed ID: 12879812
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media].
Tapia C; León E; Palavecino E
Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079
[TBL] [Abstract][Full Text] [Related]
3. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
4. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.
Maninder J; Usha A
J Commun Dis; 2008 Sep; 40(3):177-81. PubMed ID: 19245155
[TBL] [Abstract][Full Text] [Related]
5. Oral Candida isolates among HIV-infected subjects in Nigeria.
Nweze EI; Ogbonnaya UL
J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
[TBL] [Abstract][Full Text] [Related]
6. [Oro-esophageal candidiasis resistant to fluconazole in patients with AIDS].
Diz P; Ocampo A; Miralles C; Otero I; Iglesias I; Martínez C
Enferm Infecc Microbiol Clin; 1993 Jan; 11(1):36-9. PubMed ID: 8461371
[TBL] [Abstract][Full Text] [Related]
7. [Oropharyngeal candidiasis resistant to fluconazole in patients infected by HIV].
Drobacheff C; Manteaux A; Millon L; Reboux G; Barale T; Laurent R
Ann Dermatol Venereol; 1996; 123(2):85-9. PubMed ID: 8761757
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
9. Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870.
Hood SV; Hollis S; Percy M; Atkinson G; Williams K; Denning DW
Clin Infect Dis; 1999 Mar; 28(3):587-96. PubMed ID: 10194083
[TBL] [Abstract][Full Text] [Related]
10. Correlation between CLSI, EUCAST and Etest methodologies for amphotericin B and fluconazole antifungal susceptibility testing of Candida spp. clinical isolates.
Claudino AL; Peixoto RF; Melhem MS; Szeszs MW; Lyon JP; Chavasco JK; Franco MC
Pharmazie; 2008 Apr; 63(4):286-9. PubMed ID: 18468388
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of oral Candida to seven antifungal agents.
Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
[TBL] [Abstract][Full Text] [Related]
12. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Sobel JD; Ohmit SE; Schuman P; Klein RS; Mayer K; Duerr A; Vazquez JA; Rampalo A;
J Infect Dis; 2001 Jan; 183(2):286-93. PubMed ID: 11204125
[TBL] [Abstract][Full Text] [Related]
13. Oropharyngeal candidiasis in AIDS patients from Abidjan (Ivory Coast): antifungal susceptibilities and multilocus enzyme electrophoresis analysis of Candida albicans isolates.
Nébavi F; Arnavielhe S; Le Guennec R; Ménan E; Kacou A; Combe P; Aoussi E; Mallié M; Koné M; Bastide JM
Pathol Biol (Paris); 1998 May; 46(5):307-14. PubMed ID: 9769890
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis.
Martínez M; López-Ribot JL; Kirkpatrick WR; Bachmann SP; Perea S; Ruesga MT; Patterson TF
J Antimicrob Chemother; 2002 Mar; 49(3):515-24. PubMed ID: 11864952
[TBL] [Abstract][Full Text] [Related]
15. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
17. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
Nadagir SD; Chunchanur SK; Halesh LH; Yasmeen K; Chandrasekhar MR; Patil BS
Southeast Asian J Trop Med Public Health; 2008 May; 39(3):492-5. PubMed ID: 18564689
[TBL] [Abstract][Full Text] [Related]
18. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients.
Chryssanthou E; Torssander J; Petrini B
Scand J Infect Dis; 1995; 27(4):391-5. PubMed ID: 8658076
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy.
Ruhnke M; Schmidt-Westhausen A; Engelmann E; Trautmann M
J Clin Microbiol; 1996 Dec; 34(12):3208-11. PubMed ID: 8940474
[TBL] [Abstract][Full Text] [Related]
20. Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients.
Bussaratid V; Tansupasawasdikul S; Simpson A; Pitisuttithum P; Phonrat B; Howe P; White NJ
J Med Assoc Thai; 2002 Jul; 85(7):757-64. PubMed ID: 12296406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
